PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)71914-3
https://www.valueinhealthjournal.com/article/S1098-3015(11)71914-3/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
76
First Page :
A254
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71914-3&doi=10.1016/S1098-3015(11)71914-3